Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Mar 18;20(2):267–277. doi: 10.22074/cellj.2018.5197

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Any use, distribution, reproduction or abstract of this publication in any medium, with the exception of commercial purposes, is permitted provided the original work is properly cited

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Fig.1 — Flow chart for patient eligibility. We selected patients with STEMI at defined intervals from 10 days to 3 months. Ineligible patients were excluded by angiography results among other criteria as mentioned in the diagram. We divided eligible patients into three groups: placebo, MNC, and CD133⁺. All patients were intramyocardly injected 2 cc of suspension in 10 points of the marginal zone of the infarcted muscle during open heart surgery and were followed by SPECT scan at 6 and 18 months. From these patients, 8 were not available for follow up and one patient from the MNC group died. STEMI; ST elevation myocardial infarction, CABG; Coronary artery bypass graft, PCI; Percutaneous coronary intervention, LVEF; Left ventricular ejection fraction, MNC; Mononuclear cells, SPECT; Single photon emission computed tomography, and *; According to sample size calculation, we considered 90 patients for enrollment, however financial limitations forced us to stop patient recruitment. This study enrolled and randomly assigned 77 patients to three groups: MNC, CD133⁺, and placebo.